Tirzepatide Dosage Chart: Week-by-Week Titration Schedule
Your tirzepatide dose on week 1 is 2.5 mg. By week 21, it can reach 15 mg — but the path between those numbers is where most people either succeed or struggle.
The titration schedule exists for a reason: jumping too fast wrecks your GI system and often leads people to quit. Moving too slow can stall weight loss when your body is ready for more. This chart gives you the full picture — week by week, dose by dose — for both brand-name pens (Mounjaro and Zepbound) and compounded tirzepatide vials.
for all patients
at max dose over 72 weeks
dose before advancing
Key Takeaways:
- Tirzepatide starts at 2.5 mg weekly and escalates in 2.5 mg steps every 4+ weeks
- The full titration from start to max dose (15 mg) takes a minimum of 20 weeks
- Mounjaro (diabetes) and Zepbound (weight loss) use identical dosing schedules — same molecule, different labels
- Compounded tirzepatide follows the same mg amounts but comes in vials with different concentrations (5, 10, or 20 mg/mL)
- You don't have to reach 15 mg — many patients maintain results at 5–10 mg long-term
- Side effects peak during dose increases and usually settle within 1–2 weeks
The chart below is the anchor. Everything else in this guide — what to expect, when to hold, how to convert units — builds off it. Bookmark this page: you'll be coming back.
Master Tirzepatide Titration Chart (FDA-Approved Schedule)
This is the standard titration schedule for both Mounjaro and Zepbound, pulled directly from prescribing information. Each dose level requires a minimum of 4 weeks before you can advance.
| Phase | Week | Dose | Notes |
|---|---|---|---|
| Starter | 1–4 | 2.5 mg | Tolerability period — not a weight loss dose |
| Maintenance 1 | 5–8 | 5 mg | First therapeutic dose; most people see meaningful appetite reduction |
| Maintenance 2 | 9–12 | 7.5 mg | Transitional — GI side effects often peak here |
| Maintenance 3 | 13–16 | 10 mg | Optimal dose for many long-term users |
| Maintenance 4 | 17–20 | 12.5 mg | Pre-max dose; diminishing returns for some |
| Maximum | 21+ | 15 mg | Highest approved dose; reserved for those needing it |
At the fastest pace, you reach 15 mg at week 21 (just under 5 months). That's only if you tolerate every dose increase cleanly. For most people, the realistic timeline is 6–10 months to find their sweet spot — and that's perfectly fine.
For a deeper breakdown of how the full tirzepatide dosage protocol works beyond just the chart, including dosing for type 2 diabetes vs. weight loss, see our full guide.
What to Expect at Each Dose Tier
Knowing the dose number isn't enough. Here's what actually happens in your body — and in your life — as you move through the schedule.
2.5 mg (Weeks 1–4): The Warmup
This dose is designed to introduce your GI system to the medication, not to produce weight loss. Nausea is most common during this phase but is usually mild. Expect reduced appetite within the first week or two — that's the GIP/GLP-1 mechanism kicking in. Don't be discouraged if the scale doesn't move much. Your body is adjusting.
What patients commonly report:
- Mild nausea, especially 4–8 hours after injection
- Noticeably smaller appetite
- Some constipation or loose stools
- Occasional fatigue on injection day
5 mg (Weeks 5–8): First Real Results
This is where most people start losing weight meaningfully. The 5 mg dose is the first full maintenance dose. Appetite suppression gets noticeably stronger, and most people find they're naturally eating significantly less without feeling deprived. GI effects often improve here compared to the 2.5 mg transition.
Clinical data: In the SURMOUNT-1 trial, participants at 5 mg lost an average of ~15% of body weight over 72 weeks (compared to ~21% at 15 mg).
7.5 mg (Weeks 9–12): The Transition Bump
Expect a potential resurgence of nausea at this tier. The 7.5 mg step is often where people feel side effects the most sharply, especially if they rushed through the early doses. Slow down here if needed. Staying at 7.5 mg for 6–8 weeks instead of 4 is a legitimate, prescriber-supported choice.
10 mg (Weeks 13–16): The Sweet Spot for Many
The 10 mg dose has the best efficacy-to-tolerability ratio for most users. Many people find this is where they want to stay long-term. Weight loss continues at a strong pace and side effects tend to stabilize. If you're consistently losing 0.5–1% of body weight per week and tolerating it well, there's no clinical obligation to go higher.
12.5 mg (Weeks 17–20): Pre-Max
Marginal additional benefit over 10 mg for many patients, but some see meaningful improvement in blood sugar control or weight loss resumption after a plateau. GI tolerance varies significantly here — some people handle it easily, others find it rough.
15 mg (Week 21+): Maximum Dose
The highest FDA-approved dose. Clinical trials show the greatest average weight loss at this tier, but the incremental gain over 10 mg is smaller than going from 5 mg to 10 mg. Reserve this dose for patients who haven't reached target weight and are tolerating lower doses well.
Dose-Weight Loss Correlation Table
Based on SURMOUNT-1 and SURPASS clinical trial data (72 weeks of treatment):
| Dose | Average Weight Loss (% of body weight) | Average Weight Loss (lbs, 250 lb baseline) | Time to Plateau |
|---|---|---|---|
| 5 mg | ~15% | ~37 lbs | ~52–60 weeks |
| 10 mg | ~19.5% | ~49 lbs | ~60–72 weeks |
| 15 mg | ~20.9% | ~52 lbs | ~72 weeks |
Note: Individual results vary significantly. These are mean values from controlled clinical trials. Real-world results often differ based on diet, activity, and adherence.
Want to see how real people's results compare across the full protocol? Check out our tirzepatide before and after case breakdowns.
Mounjaro Pen Sizes vs. Zepbound: What's the Same, What's Different
The active ingredient is identical: tirzepatide. The titration schedule is identical. What's different is the indication, the packaging, and some pen form factors.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| FDA Indication | Type 2 diabetes management | Chronic weight management; obstructive sleep apnea (with obesity) |
| Manufacturer | Eli Lilly | Eli Lilly |
| Starting dose | 2.5 mg weekly | 2.5 mg weekly |
| Max dose | 15 mg weekly | 15 mg weekly |
| Pen format | Single-dose autoinjector pen | Single-dose autoinjector pen; also available as vials |
| Available strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL | 2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL |
| Pen color coding | Yes (each dose is a distinct color) | Yes (each dose is a distinct color) |
| Storage | Refrigerated; can be kept at room temp up to 21 days | Refrigerated; can be kept at room temp up to 21 days |
Bottom line: If you have a Mounjaro prescription but want it for weight loss, or vice versa, the dosing is identical. Insurance coverage is the main practical difference — Zepbound is more likely to be covered under weight loss benefits; Mounjaro under diabetes benefits.
Slow Titration Schedule: For GI-Sensitive Patients
Some providers recommend staying at each dose for 6–8 weeks instead of 4. This is particularly common for:
- People with a history of severe GI reactions to medications
- Patients who experienced significant nausea at the 2.5 mg or 5 mg tier
- Those seeing good results at a lower dose without reason to rush higher
| Weeks | Dose | Duration at Dose |
|---|---|---|
| 1–8 | 2.5 mg | 8 weeks |
| 9–16 | 5 mg | 8 weeks |
| 17–24 | 7.5 mg | 8 weeks |
| 25–32 | 10 mg | 8 weeks |
| 33–40 | 12.5 mg | 8 weeks |
| 41+ | 15 mg | Ongoing |
Reaching 15 mg on this schedule takes about 40 weeks (~10 months). The tradeoff — fewer side effects, more gradual progression — is worth it for many patients.
Compounded Tirzepatide Dosage Chart: mL and Units Conversion
Compounded tirzepatide comes in multi-dose vials at varying concentrations. The dose in milligrams is the same as brand-name; the difference is you draw your dose using a syringe, and you need to convert mg → units based on your vial's concentration.
How to calculate your draw volume:
Units to draw = (Dose in mg ÷ Concentration in mg/mL) × 100
At 10 mg/mL Concentration (Most Common)
| Dose | Volume (mL) | Units to Draw (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 units |
| 5 mg | 0.50 mL | 50 units |
| 7.5 mg | 0.75 mL | 75 units |
| 10 mg | 1.00 mL | 100 units |
| 12.5 mg | 1.25 mL | 125 units* |
| 15 mg | 1.50 mL | 150 units* |
*May require a 1.5 mL syringe or two injections.
At 5 mg/mL Concentration
| Dose | Volume (mL) | Units to Draw (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.50 mL | 50 units |
| 5 mg | 1.00 mL | 100 units |
| 7.5 mg | 1.50 mL | 150 units* |
| 10 mg | 2.00 mL | 200 units* |
*Requires multiple injections; 5 mg/mL is not recommended for doses above 5 mg.
At 20 mg/mL Concentration
| Dose | Volume (mL) | Units to Draw (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.125 mL | ~13 units |
| 5 mg | 0.25 mL | 25 units |
| 7.5 mg | 0.375 mL | ~38 units |
| 10 mg | 0.50 mL | 50 units |
| 12.5 mg | 0.625 mL | ~63 units |
| 15 mg | 0.75 mL | 75 units |
Always confirm the concentration on your vial label before drawing. Compounding pharmacies use different concentrations, and a dosing error at a higher concentration can mean a significant accidental overdose.
When to Hold vs. When to Advance Your Dose
This is the decision most people get wrong — either rushing up too fast or staying at a dose that's no longer working. Here's a practical framework:
✅ Advance to the Next Dose When:
- You've been at the current dose for at least 4 weeks (or 6–8 weeks on a slow protocol)
- Side effects from the current dose have resolved or are minimal
- Weight loss has stalled for 3+ consecutive weeks at the current dose
- Your prescriber agrees based on your check-in
⏸ Hold at Your Current Dose When:
- You're still actively losing weight (there's no reason to rush higher)
- Side effects are present but improving week over week
- You've just recovered from an illness, surgery, or significant stress
- You're entering a travel period and don't want to adjust variables
⬇ Drop Back a Dose When:
- Nausea, vomiting, or diarrhea is severe and not improving after 2 weeks
- You've lost more than 1.5% of body weight per week for 3+ consecutive weeks (too fast)
- Your prescriber recommends it based on labs or clinical assessment
- You feel physically depleted (muscle loss signs, fatigue, inability to eat)
One key principle: The goal is the dose that works, not the highest dose possible. Plenty of people have excellent, sustainable results at 5 mg or 7.5 mg. Chasing 15 mg when 10 mg is working is counterproductive.
For a complete breakdown of what happens at each dose, including how to manage the side effect profile by tier, see our tirzepatide side effects guide.
Missed Dose Protocol
Tirzepatide's long half-life (~5 days) gives you some flexibility:
- Missed by ≤4 days: Take it as soon as you remember, then resume your normal weekly schedule
- Missed by >4 days: Skip the missed dose entirely — take your next dose on your regularly scheduled day
- Never double-dose to compensate for a missed injection
If you miss two consecutive doses, GI side effects may return when you restart, similar to starting fresh. Talk to your prescriber if you anticipate a prolonged interruption.
CTA: Need a Reliable Source for Tirzepatide?
If you're looking for compounded tirzepatide from a verified, quality-tested source, Ascension Peptides is one of the most trusted options available. They ship to most US states and offer multiple concentrations that align with the dosing charts above.
Frequently Asked Questions
Q: Can I stay at 2.5 mg long-term if it's working?
A: The 2.5 mg dose is considered a tolerability starter dose, not a maintenance dose. Clinical trials used 5 mg as the minimum maintenance dose for weight loss. Most prescribers will encourage moving to 5 mg after 4 weeks. If you're seeing results, staying at 5 mg is a much more supported choice than staying at 2.5 mg.
Q: What if I feel terrible at 5 mg — do I have to push through?
A: No. If side effects are severe, you can drop back to 2.5 mg and wait until symptoms resolve before trying 5 mg again. You can also slow the ramp by extending time at each tier to 6–8 weeks. The goal is tolerability, not speed.
Q: Is the compounded tirzepatide titration schedule the same as brand-name?
A: The mg doses are identical. The difference is how you measure and administer them — compounded comes in vials requiring syringe draws, so you need to account for concentration. Always verify your calculation before injecting.
Q: How is Mounjaro different from Zepbound if they're the same drug?
A: The molecule (tirzepatide) and dosing schedule are identical. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. The primary difference in practice is insurance coverage — which indication is covered depends on your plan.
Q: What's the maximum dose of tirzepatide?
A: 15 mg per week is the maximum FDA-approved dose for both Mounjaro and Zepbound. Some compounding protocols go higher, but there is no clinical trial data supporting doses above 15 mg and the risk-benefit ratio is unknown.
Q: Why does the titration schedule take so long?
A: GLP-1 and GIP receptor agonists like tirzepatide affect the GI system significantly. Moving too fast through dose increases overwhelms the digestive system and causes the nausea, vomiting, and diarrhea that lead most people to quit. The 4-week minimum at each tier isn't arbitrary — it's the minimum time needed for GI adaptation to stabilize.
Q: Can I split my weekly dose into two injections to reduce side effects?
A: This is sometimes done with compounded tirzepatide (since you control the syringe volume), but it's off-label and not supported by Mounjaro/Zepbound autoinjector pens. Some providers recommend split dosing for patients with persistent nausea. Discuss with your prescriber before attempting this.
Quick Reference Summary
| Dose | Brand Pen Available | Min. Duration | Expected Weekly Weight Loss | Common Side Effects |
|---|---|---|---|---|
| 2.5 mg | Mounjaro / Zepbound | 4 weeks | Minimal (tolerability phase) | Nausea, appetite changes |
| 5 mg | Mounjaro / Zepbound | 4 weeks | 0.5–1% of body weight | Nausea (reducing), constipation |
| 7.5 mg | Mounjaro / Zepbound | 4 weeks | 0.5–1% of body weight | GI peak — nausea possible |
| 10 mg | Mounjaro / Zepbound | 4 weeks | 0.5–1% of body weight | Side effects typically stabilize |
| 12.5 mg | Mounjaro / Zepbound | 4 weeks | 0.4–0.8% of body weight | Variable |
| 15 mg | Mounjaro / Zepbound | Ongoing | 0.3–0.7% of body weight | GI effects may recur at max |
This content is for informational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication. Dosing decisions should be made in consultation with a licensed healthcare provider. Individual results vary. The titration schedule above reflects FDA-approved prescribing information for Mounjaro and Zepbound as of the publication date.
